CN115161283B - Composition for directional differentiation and culture of liver portal bile duct cancer-derived organoids and application thereof - Google Patents
Composition for directional differentiation and culture of liver portal bile duct cancer-derived organoids and application thereof Download PDFInfo
- Publication number
- CN115161283B CN115161283B CN202210724972.XA CN202210724972A CN115161283B CN 115161283 B CN115161283 B CN 115161283B CN 202210724972 A CN202210724972 A CN 202210724972A CN 115161283 B CN115161283 B CN 115161283B
- Authority
- CN
- China
- Prior art keywords
- concentration
- organoid
- culture
- growth factor
- bsa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000002220 organoid Anatomy 0.000 title claims abstract description 90
- 208000006990 cholangiocarcinoma Diseases 0.000 title claims abstract description 25
- 206010004593 Bile duct cancer Diseases 0.000 title claims abstract description 14
- 208000026900 bile duct neoplasm Diseases 0.000 title claims abstract description 14
- 230000004069 differentiation Effects 0.000 title claims abstract description 12
- 210000004185 liver Anatomy 0.000 title abstract description 26
- 239000000203 mixture Substances 0.000 title abstract description 13
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims abstract description 27
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims abstract description 27
- 102400000921 Gastrin Human genes 0.000 claims abstract description 27
- 108010052343 Gastrins Proteins 0.000 claims abstract description 27
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims abstract description 27
- 101800003838 Epidermal growth factor Proteins 0.000 claims abstract description 25
- 229940116977 epidermal growth factor Drugs 0.000 claims abstract description 25
- 229940126864 fibroblast growth factor Drugs 0.000 claims abstract description 25
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract description 25
- 210000001519 tissue Anatomy 0.000 claims description 43
- 230000029087 digestion Effects 0.000 claims description 24
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 23
- 239000006285 cell suspension Substances 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 102000029816 Collagenase Human genes 0.000 claims description 18
- 108060005980 Collagenase Proteins 0.000 claims description 18
- 229960002424 collagenase Drugs 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 17
- 239000006228 supernatant Substances 0.000 claims description 14
- 238000004140 cleaning Methods 0.000 claims description 12
- 230000002440 hepatic effect Effects 0.000 claims description 11
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 claims description 9
- 239000003112 inhibitor Substances 0.000 claims description 9
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 8
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 7
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 7
- 239000003102 growth factor Substances 0.000 claims description 7
- 239000013589 supplement Substances 0.000 claims description 7
- 239000001963 growth medium Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 5
- 239000007995 HEPES buffer Substances 0.000 claims description 5
- 230000004156 Wnt signaling pathway Effects 0.000 claims description 4
- 239000012574 advanced DMEM Substances 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 230000001079 digestive effect Effects 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 239000011435 rock Substances 0.000 claims description 4
- 238000010008 shearing Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 3
- 102000018386 EGF Family of Proteins Human genes 0.000 claims description 2
- 108010066486 EGF Family of Proteins Proteins 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 230000006862 enzymatic digestion Effects 0.000 claims description 2
- 238000001976 enzyme digestion Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000012090 serum-supplement Substances 0.000 claims description 2
- 238000012136 culture method Methods 0.000 claims 2
- 230000004083 survival effect Effects 0.000 abstract description 3
- 102400001368 Epidermal growth factor Human genes 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 26
- 201000011510 cancer Diseases 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 238000007664 blowing Methods 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 2
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 2
- 101000998011 Homo sapiens Keratin, type I cytoskeletal 19 Proteins 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000007666 Klatskin Tumor Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000018060 hilar cholangiocarcinoma Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/345—Gastrin; Cholecystokinins [CCK]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/415—Wnt; Frizzeled
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a composition for directional differentiation and culture of liver portal bile duct cancer-derived organoids and application thereof, wherein the composition comprises an epidermal growth factor, a fibroblast growth factor and gastrin; the concentration of the epidermal growth factor is 5-100ng/ml, the concentration of the fibroblast growth factor is 50-250ng/ml, and the concentration of the gastrin is 1-50nM. The composition provided by the invention can effectively improve the survival rate of the liver portal bile duct cancer organoid, so that the liver portal bile duct cancer organoid can be stably passaged for a plurality of times.
Description
Technical Field
The invention belongs to the field of tumor biology, and particularly relates to a composition for directional differentiation and culture of liver portal biliary duct cancer source organoids and application thereof.
Background
Liver portal cholangiocarcinoma (Hilar cholangiocarcinoma, HCCA) is a very heterogeneous, highly malignant cholangiocarcinoma, and radical excision surgery and chemotherapy are the main approaches to treat cholangiocarcinoma. Because bile duct cancer has complicated anatomical positions and invasive growth characteristics, radical excision operation is difficult to treat, high in risk, low in radical excision rate, easy to relapse and poor in prognosis. Chemotherapy is typically a gemcitabine/cisplatin-based chemotherapy combination with limited sensitivity.
The organoid is used as a novel disease model, not only reserves the genetic background of a primary tumor focus, can reproduce a tissue structure, but also has the differentiation and proliferation potential and self-renewing capacity, has the advantages of high operability, timeliness, low economy and ethical risk, and is an ideal in-vitro model for screening personalized antitumor drugs. The Science journal reports that patient-derived organoids (Patient derived organoids, PDOs) have 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value in predicting the effectiveness of anticancer drugs. As a preclinical model, the organoids have obvious advantages in screening personalized antitumor drugs, researching tumorigenic development mechanisms and the like.
Compared with an in vitro cell model and an in vivo PDX model, the organoid culture model has great advantages in drug screening, can screen out personalized chemotherapy or targeted drugs suitable for patients more conveniently and economically, provides reliable medication guidance for patients, and avoids invalid treatment schemes for patients or finds the most effective treatment scheme with minimal side effects for patients. In addition, some of the genes that occur in conventional tumor cell lines during long-term passage are expressed either in an increased or decreased amount, and the cell surface antigens are altered, resulting in non-reproducible experimental results. The organoid technology can be combined with the genetic modification technology, and can provide a more reliable and clinical cell model for basic research of the hepatic portal cholangiocarcinoma.
Although clinical chemotherapeutics and small molecule targeted drugs are rich in variety, in clinical treatment of HCCA, few effective targeted drugs are provided for patients because of small individual differences and large tumor heterogeneity, and clinical tests applied to hepatic portal cholangiocarcinoma are few, so that personalized accurate treatment by using organoids is a new direction of clinical treatment of HCCA. In recent years, organoid technology has been widely used in various tumor studies of pancreatic cancer, colorectal cancer, lung cancer, and the like. However, in the field of cholangiocarcinoma, especially HCCA research, organoids are rarely studied.
Cytokines have a very pronounced effect on organoid activity, growth rate, direction of cell differentiation, etc. In order to simulate the signal factor environment of tumor growth in vivo as much as possible, stem cells or organ progenitor cells are proliferated and differentiated into organ-specific cell aggregates in the environment, and cytokines and small molecules used by different organoid technologies are different. For colorectal cancer derived organoids, p38 MAP kinase inhibitors are the essential small molecules, while for lung cancer derived organoids ALK5 inhibitors, recombinant human activin-a are the essential small molecules and cytokines. However, cytokines necessary for the survival environment of HCCA organoids are not clear, and organoids derived from normal cholangiocytes gradually differentiate into functional hepatocytes, which is very disadvantageous for maintaining the genetic characteristics of organoid-derived patients, so that it is very necessary and highly desirable to explore a specific culture system suitable for HCCA organoids.
Disclosure of Invention
In view of the above-mentioned shortcomings in the prior art, an object of the present invention is to provide a composition for directional differentiation and culture of liver portal biliary duct cancer-derived organoids, which comprises epidermal growth factor, fibroblast growth factor, gastrin, and uses thereof; the concentration of the epidermal growth factor is 5-100ng/ml, the concentration of the fibroblast growth factor is 50-250ng/ml, and the concentration of the gastrin is 1-50nM. The composition provided by the invention can effectively improve the survival rate of the liver portal bile duct cancer organoid, so that the liver portal bile duct cancer organoid can be stably passaged for a plurality of times.
The technical scheme of the invention is as follows:
a composition for targeted differentiation and culture of a hepatic portal cholangiocarcinoma-derived organoid, the composition comprising an epidermal growth factor, a fibroblast growth factor, a gastrin; the concentration of the epidermal growth factor is 5-100ng/ml, the concentration of the fibroblast growth factor is 50-250ng/ml, and the concentration of the gastrin is 1-50nM.
According to the invention, the epidermal growth factor, the fibroblast growth factor and the gastrin are respectively combined with the receptor specific recognition by adding the epidermal growth factor, the fibroblast growth factor and the gastrin into the liver portal bile duct cancer source organoid to cooperatively promote the growth of the liver portal bile duct cancer source organoid.
Preferably, the concentration of the epidermal growth factor is 50ng/ml, the concentration of the fibroblast growth factor is 100ng/ml, and the concentration of the gastrin is 10nM.
Preferably, the composition for targeted differentiation and culture of a hepatic cholangiocarcinoma derived organoid further comprises a Wnt signaling pathway agonist, a ROCK inhibitor, a BMP inhibitor, a non-serum supplement, and Primocin.
Preferably, the Wnt signaling pathway agonist is selected from Wnt-3a or/and R-Sponding1.
Preferably, the ROCK inhibitor is selected from Y-27632 or/and a83-01.
Preferably, the BMP inhibitor is selected from hNoggin.
Preferably, the non-serum additive is selected from the group consisting of B27, nicotinamide or/and N-acetylcsteine.
Preferably, the concentration of Wnt-3a is 20ng/ml.
Preferably, the concentration of R-Sponding1 is 500ng/ml.
Preferably, the concentration of Y-27632 is 10.5M.
Preferably, the concentration of A83-01 is 500nM.
Preferably, the concentration of hNoggin is 100ng/ml.
Preferably, the concentration of B27 is 1×.
Preferably, the concentration of Nicotinamide is 10mM.
Preferably, the concentration of N-acetylcsteine is 1.25mM.
Preferably, the Primocin concentration is 100 μg/ml.
Still another object of the present invention is to provide a method for directional differentiation and culture of a hepatic portal cholangiocarcinoma-derived organoid, comprising the steps of:
s1, removing burnt tissues and fat tissues on bile duct cancer tissues of the hepatic portal part, and shearing and enzyme digestion to obtain single-cell suspension;
s2, uniformly mixing the single cell suspension with matrix glue with low growth factors, and adding a complete culture medium containing the epidermal growth factors, the fibroblast growth factors and the gastrin for culture to obtain a hepatic portal bile duct cancer source organoid;
the concentration of the epidermal growth factor is 5-100ng/ml, the concentration of the fibroblast growth factor is 50-250ng/ml, and the concentration of the gastrin is 1-50nM.
Preferably, the concentration of the epidermal growth factor is 50ng/ml, the concentration of the fibroblast growth factor is 100ng/ml, and the concentration of the gastrin is 10nM.
Preferably, in step S1, the specific steps of the enzymatic digestion are as follows:
adding preheated digestive juice into sheared tissue fragments, uniformly mixing, centrifuging, digesting, dispersing, standing, separating supernatant after massive tissue fragments settle, adding a BSA-containing organoid cleaning solution into the supernatant to terminate digestion, centrifuging, discarding the supernatant, and adding a BSA-containing organoid cleaning solution to precipitate to obtain a cell suspension;
step b, repeating the digestion method in the step a on the massive tissue fragments in the step a to obtain a cell suspension;
c, repeating the digestion method in the step a on the massive tissue fragments in the step b to obtain a cell suspension;
and d, filtering the cell suspension obtained in the steps a, b and c, centrifuging, discarding supernatant, adding the organoid cleaning solution containing BSA for resuspension, and centrifuging to obtain a precipitate, namely the single cell suspension.
The invention obtains HCCA tissue single cells by separating through the steps of object understanding, enzymolysis digestion, natural sedimentation and the like in sequence, inoculates the HCCA tissue single cells into low growth factor matrigel, carries out 3D culture by using an HCCA organoid induction culture medium, dynamically observes the morphology and growth condition of the organoid through a microscopic imaging system after the inoculation is finished, and photographs and records the organoid. The HCCA organoids are separated and cultured by utilizing a three-step digestion method, the tissue is subjected to enzymolysis by using a plurality of digestive enzyme mixed solutions, the contact area of the tissue and enzymes is increased, the tissue is digested more thoroughly, repeated objects are understood to be separated and naturally settled repeatedly, the number of single cells obtained from the HCCA tissue is effectively increased, the cells on the surface of the tissue block are prevented from being in the digestive solution for a long time after falling off, the cell activity can be maintained, the success rate of organoid culture is improved, and a more reliable and clinical cell model is provided for the follow-up exploration of the molecular mechanism of HCCA generation, the personalized medicine guide of HCCA patients and the development of new medicines.
Preferably, in step a, the digestion solution contains 10. Mu.g/ml collagenase type I, 5mg/ml collagenase type II, 10. Mu.g/ml collagenase type III and 10. Mu.g/ml deoxyribonuclease type I.
Preferably, in step a, the BSA-containing organoid wash has a BSA mass concentration of 0.1%.
Preferably, in step a, the BSA-containing organoid wash is Advanced DMEM/F-12 containing 10mM HEPES, 1x GlutaMAX Supplement and 100 μg/ml Primocin at a pH of 7.2-7.5.
Preferably, in step S2, the low growth factor matrigel is used in an amount of 2×10 5 Individual cells/ml.
Drawings
FIG. 1. HCCA organoids of example 1 grew and morphologically changed (scale: 100 μm) on days 1, 3, 7, and 14 under the same field of view.
FIG. 2. (A) similarity between HCCA organoids and primary tumor tissue of example 1 (scale 100 μm); (B) Expression of biliary epithelial markers CK19, MUC1 in HCCA organoids of example 1 (scale 100 μm).
FIG. 3 ratio of living to dead cells of HCCA organoids of examples 1-3 and comparative examples 1-4.
Detailed Description
In order to make the technical solution of the present invention better understood by those skilled in the art, the technical solution of the present invention will be clearly and completely described in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the present invention without making any inventive effort, shall fall within the scope of the present invention.
Terminology:
HCCA: portal biliary duct cancer.
BSA: bovine serum albumin.
HEPES: 4-hydroxyethyl piperazine ethanesulfonic acid.
GlutaMAX Supplement: glutamine substitutes.
Primocin: an antibiotic.
PGE2: prostaglandin E2.
Example 1: isolated culture of liver portal biliary duct cancer-derived organoids.
Step A, rapidly placing the obtained HCCA specimen into a serum-free 1640 cell culture medium after surgical excision, preserving at 4 ℃, and transferring to a sterile cell operation table for separation operation within 4 hours;
step B, removing burnt tissues and adipose tissues on the HCCA specimen, and shearing the tissues to 5mm as much as possible 3 Left and right size;
adding about 3 times of volume of tissue fragments of 37 ℃ preheated digestive juice containing 10 mug/mL collagenase type I, 5mg/mL collagenase type II, 10 mug/mL collagenase type III and 10 mug/mL deoxyribonuclease type I into sheared tissue fragments, blowing and mixing uniformly, and transferring to a centrifuge tube, digesting for 20min at 37 ℃ and 35rpm, vigorously blowing and beating the digested tissue-digestive juice mixture by a Pasteur pipe until the adhered tumor fragments are completely dispersed, standing at room temperature for about 5min, transferring the supernatant to another centrifuge tube after the massive tissue fragments settle, adding an organoid cleaning liquid with the same volume of BSA (BSA) with the mass concentration of 0.1%, stopping digestion, centrifuging for 5min at 250g and 4 ℃, discarding the supernatant, adding 1mL organoid cleaning liquid containing BSA, re-suspending and precipitating to obtain a cell suspension O, and preserving on ice;
d, repeating the digestion method in the step C on the settled massive tissue fragments in the step C to obtain a cell suspension P, and preserving the cell suspension P on ice;
step E, repeating the digestion method in the step C for the settled massive tissue fragments in the step D (the digestion time can be properly prolonged until the tissues are almost completely digested by naked eyes), so as to obtain a cell suspension Q, and preserving the cell suspension on ice;
step F, combining the cell suspensions O, P, Q by a 70 μm filter screen, centrifuging at 250g and 4 ℃ for 5min, discarding the supernatant (the precipitation is observed at this time, if the content of red blood cells is high, the red blood cells are required to be lysed), adding a BSA-containing organoid cleaning solution for resuspension, and centrifuging at 250g and 4 ℃ for 5min to obtain the precipitation which is HCCA tumor tissue single cells;
step G. After cell counting, the cells were resuspended to 2X10 with a BSA-containing organoid wash 5 The concentration of individual cells/mL, adding low growth factor matrigel thawed on ice in equal volume, dripping into a cell pore plate preheated at 37 ℃, and adding complete culture medium for culture after solidification;
the organoid wash of BSA is Advanced DMEM/F-12 containing 10mM HEPES, 1x GlutaMAX Supplement and 100 μg/ml Primocin at pH 7.2-7.5;
the complete culture medium is an organoid wash of 50ng/ml epidermal growth factor, 100ng/ml fibroblast growth factor, 10nM gastrin, 20ng/ml Wnt-3a, 500ng/ml R-Spondin1, 10.5M Y-27632, 500nM A83-01, 100ng/ml hNoggin, 1 XB 27 Supplement, 10mM Nicotinamide, 1.25mM N-acetylcsteine, 100 μg/ml Primocin.
Example 2: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was repeated except that 50ng/ml of the epidermal growth factor, 100ng/ml of the fibroblast growth factor, 10nM of the gastrin was replaced with 5ng/ml of the epidermal growth factor, 250ng/ml of the fibroblast growth factor, and 1nM of the gastrin.
Example 3: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was repeated except that 50ng/ml of the epidermal growth factor, 100ng/ml of the fibroblast growth factor and 10nM of the gastrin of example 1 were replaced with 100ng/ml of the epidermal growth factor, 50ng/ml of the fibroblast growth factor and 50nM of the gastrin.
Comparative example 1: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was repeated except that 50ng/ml of the epidermal growth factor, 100ng/ml of the fibroblast growth factor and 10nM of the gastrin were replaced with 50ng/ml of the epidermal growth factor and 100ng/ml of the fibroblast growth factor in example 1.
Comparative example 2: isolated culture of liver portal biliary duct cancer-derived organoids.
The remainder of the procedure in example 1 was followed except that 50ng/ml of the epidermal growth factor, 100ng/ml of the fibroblast growth factor, 10nM of the gastrin in example 1 was replaced with 100ng/ml of the fibroblast growth factor, 10nM of the gastrin.
Comparative example 3: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was repeated except that 50ng/ml of the epidermal growth factor, 100ng/ml of the fibroblast growth factor and 10nM of the gastrin of example 1 were replaced with 50ng/ml of the epidermal growth factor and 10nM of the gastrin.
Comparative example 4: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was repeated except that 50ng/ml of the epidermal growth factor, 100ng/ml of the fibroblast growth factor, 10nM of the gastrin was replaced with 50ng/ml of the epidermal growth factor, 100ng/ml of the fibroblast growth factor, 10nM of the gastrin, and PGE2 1. Mu.M.
Comparative example 5: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was repeated except that the digestion solution of example 1 contained 10. Mu.g/ml collagenase type I, 5mg/ml collagenase type II, 10. Mu.g/ml collagenase type III and 10. Mu.g/ml deoxyribonuclease type I were replaced with the digestion solution containing 10. Mu.g/ml collagenase type I.
Comparative example 6: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was repeated except that the digestion solution of example 1 contained 10. Mu.g/ml collagenase type I, 5mg/ml collagenase type II, 10. Mu.g/ml collagenase type III and 10. Mu.g/ml deoxyribonuclease type I in place of the digestion solution of 5mg/ml collagenase type II.
Comparative example 7: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was repeated except that the digestion solution of example 1 contained 10. Mu.g/ml collagenase type I, 5mg/ml collagenase type II, 10. Mu.g/ml collagenase type III and 10. Mu.g/ml deoxyribonuclease type I were replaced with the digestion solution containing 10. Mu.g/ml collagenase type III.
Comparative example 8: isolated culture of liver portal biliary duct cancer-derived organoids.
The procedure of example 1 was followed except that the digestions of example 1 contained 10. Mu.g/ml collagenase type I, 5mg/ml collagenase type II, 10. Mu.g/ml collagenase type III and 10. Mu.g/ml deoxyribonuclease I were replaced with the digestions containing 10. Mu.g/ml deoxyribonuclease I.
Comparative example 9: isolated culture of liver portal biliary duct cancer-derived organoids.
Step A, rapidly placing the obtained HCCA specimen into a serum-free 1640 cell culture medium after surgical excision, preserving at 4 ℃, and transferring to a sterile cell operation table for separation operation within 4 hours;
step B, removing burnt tissues and adipose tissues on the HCCA specimen, and shearing the tissues to 5mm as much as possible 3 Left and right size;
adding about 3 times of volume of tissue fragments to pre-heat digestion liquid at 37 ℃ at 10 mug/mL collagenase type I, 5mg/mL collagenase type II, 10 mug/mL collagenase type III and 10 mug/mL deoxyribonuclease type I, blowing and mixing uniformly, and transferring to a centrifuge tube, digesting for 20min at 37 ℃ and 35rpm, vigorously blowing and beating the digested tissue-digestion liquid mixture by a Pasteur pipe until the adhered tumor fragments are completely dispersed, standing at room temperature for about 5min, transferring the supernatant to another centrifuge tube after the large tissue fragments settle, adding an organoid cleaning liquid with the same volume of BSA (BSA) with the mass concentration of 0.1%, stopping digestion, centrifuging for 5min at 250g and 4 ℃, discarding the supernatant, adding 1mL organoid cleaning liquid with BSA, re-suspending and precipitating to obtain a cell suspension, and preserving on ice;
step D, combining the cell suspensions through a 70 μm filter screen, centrifuging at 250g and 4 ℃ for 5min, discarding the supernatant (at this time, observing precipitation, if the content of red blood cells is high, then cracking red blood cells), adding a BSA-containing organoid cleaning solution for resuspension, and centrifuging at 250g and 4 ℃ for 5min to obtain the precipitate which is HCCA tumor tissue single cells;
step E. After cell counting, the cells are resuspended to 2X10 with a BSA-containing organoid wash 5 The concentration of individual cells/mL, adding low growth factor matrigel thawed on ice in equal volume, dripping into a cell pore plate preheated at 37 ℃, and adding complete culture medium for culture after solidification;
the organoid wash of BSA is Advanced DMEM/F-12 containing 10mM HEPES, 1x GlutaMAX Supplement and 100 μg/ml Primocin at pH 7.2-7.5;
the complete medium is an organoid wash containing 50ng/ml epidermal growth factor, 100ng/ml fibroblast growth factor, 10nM gastrin, 20ng/ml Wnt-3a, 500ng/ml R-Spondin1, 10.5M Y-27632, 500nM A83-01, 100ng/ml hNoggin, 1 XB 27 Supplement, 10mM Nicotinamide, 1.25mM N-acetylcsteine, 100 μg/ml Primocin.
Performance test: the HCCA organoid morphological changes of example 1 (see fig. 1) and HCCA organoids were identified (see fig. 2), the ratio of living and dead cells of examples 1-3 and comparative examples 1-4 (see fig. 3).
As can be seen from FIG. 1, a portion of the cell volume of the patient-derived HCCA organoids prepared by successful isolation was found to increase, clear, round under the microscope 24h after plating, and then gradually became clear and increasingly spherical.
As can be seen from FIG. 2A, the spherical cultures were paraffin-fixed and sectioned and H & E stained, and by comparison with corresponding patient tissue sections, the morphology of the nuclei was found to be consistent with that of tumor cells in the patient tissue sections, the nuclei were stained with large depths, and a partial nuclear division image was present.
As can be seen from fig. 2B, the hepatic portal cholangiocarcinoma mainly originated from biliary epithelial cells, and immunofluorescent staining of the spherical culture revealed that biliary epithelial cell markers MUC1 and CK19 were positive, indicating that the culture was derived from epithelial tissue.
As can be seen from FIG. 3, the growth factors prepared in examples 1-3 were used for isolated culture of the liver portal biliary duct cancer-derived organoids, and the organoids were produced more efficiently, so that the liver portal biliary duct cancer organoids could be stably passaged multiple times.
The number of capsular structures having a diameter of greater than 50um was observed under the mirror on day 3 after the first tissue separation of examples 1-3 and comparative examples 1-9, which showed that the number of organoids of examples 1-3 was all greater than 10 per well on day 3 and the number of organoids of comparative examples 1-9 was all less than 6 per well on day 3.
The initial single cell numbers obtained after the first tissue separation of the organoids of examples 1 to 3 and comparative examples 5 to 9 showed that the initial single cell numbers obtained after the first tissue separation of the organoids of examples 1 to 3 were 80 to 100 ten thousand/case, and the initial single cell numbers obtained after the first tissue separation of the organoids of comparative examples 5 to 9 were 40 to 60 ten thousand/case.
In conclusion, the results prove that the spherical culture has similar components with the HCCA patient from which the spherical culture is derived, accords with the characteristics of organoids, can obtain purer HCCA organoids after stable passage for 3-4 times, and can be continuously used for subsequent drug screening or other in-vitro and in-vivo experiments.
Finally, it should be noted that the above-mentioned embodiments are merely for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the above-mentioned embodiments, it should be understood by those skilled in the art that modifications and equivalents may be made to the specific embodiments of the present invention after reading the present specification, and these modifications and variations do not depart from the scope of the invention as claimed in the pending claims.
Claims (3)
1. A method for directional differentiation and culture of a hepatic portal cholangiocarcinoma-derived organoid, comprising the steps of:
s1, removing burnt tissues and fat tissues on bile duct cancer tissues of the hepatic portal part, and shearing and enzyme digestion to obtain single-cell suspension;
s2, uniformly mixing the single cell suspension with matrix glue with low growth factors, and adding a complete culture medium containing the epidermal growth factors, the fibroblast growth factors and the gastrin for culture to obtain a hepatic portal bile duct cancer source organoid;
the concentration of the epidermal growth factor is 50ng/ml, the concentration of the fibroblast growth factor is 100ng/ml, and the concentration of the gastrin is 10nM;
in step S1, the specific steps of the enzymatic digestion are as follows:
adding preheated digestive juice into sheared tissue fragments, uniformly mixing, centrifuging, digesting, dispersing, standing, separating supernatant after massive tissue fragments settle, adding a BSA-containing organoid cleaning solution into the supernatant to terminate digestion, centrifuging, discarding the supernatant, and adding a BSA-containing organoid cleaning solution to precipitate to obtain a cell suspension;
step b, repeating the digestion method in the step a on the massive tissue fragments in the step a to obtain a cell suspension;
c, repeating the digestion method in the step a on the massive tissue fragments in the step b to obtain a cell suspension;
step d, filtering the cell suspension obtained in the steps a, b and c, centrifuging, discarding supernatant, adding the organoid cleaning solution containing BSA for resuspension, and centrifuging to obtain a precipitate, namely single cell suspension;
in step a, the digestion solution contains 10. Mu.g/ml collagenase type I, 5mg/ml collagenase type II, 10. Mu.g/ml collagenase type III and 10. Mu.g/ml deoxyribonuclease type I;
the complete medium further comprises Wnt signaling pathway agonists, ROCK inhibitors, BMP inhibitors, non-serum supplements, and Primocin;
the Wnt signaling pathway agonist is selected from Wnt-3a and R-Sponding1;
the ROCK inhibitor is selected from Y-27632 and A83-01;
the BMP inhibitor is hNoggin;
the non-serum additive is selected from the group consisting of B27, nicotinamide and N-acetylcsteine;
the concentration of Wnt-3a is 20ng/ml;
the concentration of the R-Sponding1 is 500ng/ml;
the concentration of Y-27632 is 10.5M;
the concentration of A83-01 is 500nM;
the concentration of hNoggin is 100ng/ml;
the concentration of B27 is 1X;
the concentration of Nicotinamide is 10mM;
the concentration of the N-acetylcsteine is 1.25mM;
the Primocin concentration was 100 μg/ml.
2. The directional differentiation and culture method according to claim 1, wherein in step a, the BSA-containing organoid wash has a BSA mass concentration of 0.1%.
3. The directed differentiation and culture method according to claim 1, wherein in step a, the BSA-containing organoid wash is Advanced DMEM/F-12 containing 10mM HEPES, 1x GlutaMAX Supplement and 100 μg/ml Primocin at a pH of 7.2-7.5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210724972.XA CN115161283B (en) | 2022-06-24 | 2022-06-24 | Composition for directional differentiation and culture of liver portal bile duct cancer-derived organoids and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210724972.XA CN115161283B (en) | 2022-06-24 | 2022-06-24 | Composition for directional differentiation and culture of liver portal bile duct cancer-derived organoids and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115161283A CN115161283A (en) | 2022-10-11 |
| CN115161283B true CN115161283B (en) | 2024-02-02 |
Family
ID=83486451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210724972.XA Active CN115161283B (en) | 2022-06-24 | 2022-06-24 | Composition for directional differentiation and culture of liver portal bile duct cancer-derived organoids and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115161283B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116555166B (en) * | 2023-07-10 | 2024-02-20 | 苏州近岸蛋白质科技股份有限公司 | Composition for preparing rat bile duct organoids, preparation method and application of rat bile duct organoids |
| CN117004571A (en) * | 2023-07-29 | 2023-11-07 | 兰州大学第一医院 | Human hilar bile duct carcinoma sarcoma cell line CBC2T-2 and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317790A (en) * | 2019-07-22 | 2019-10-11 | 中山大学孙逸仙纪念医院 | A method of separation and in vitro culture Tissues of Human Adenocarcinoma of Pancreas organoid |
| CN111903603A (en) * | 2020-07-17 | 2020-11-10 | 浙江科途医学科技有限公司 | Transplant for constructing bile duct cancer xenograft model and preparation method and application thereof |
| WO2022109302A1 (en) * | 2020-11-20 | 2022-05-27 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015261380B2 (en) * | 2014-05-16 | 2021-04-15 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved culture method for organoids |
| WO2020206999A1 (en) * | 2019-04-11 | 2020-10-15 | 北京基石生命科技有限公司 | Method for culturing primary cells of gastric cancer and gallbladder and bile duct cancer, and supporting reagents |
-
2022
- 2022-06-24 CN CN202210724972.XA patent/CN115161283B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110317790A (en) * | 2019-07-22 | 2019-10-11 | 中山大学孙逸仙纪念医院 | A method of separation and in vitro culture Tissues of Human Adenocarcinoma of Pancreas organoid |
| CN111903603A (en) * | 2020-07-17 | 2020-11-10 | 浙江科途医学科技有限公司 | Transplant for constructing bile duct cancer xenograft model and preparation method and application thereof |
| WO2022109302A1 (en) * | 2020-11-20 | 2022-05-27 | New York University | Anti-galectin-9 antibodies and therapeutic uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| Patient-Derived Organoids of Cholangiocarcinoma;Maier CF 等;《Int J Mol Sci》;第22卷(第16期);第1-18页 * |
| 肝胆肿瘤模型与精准药物筛选新技术;刘壮 等;《临床肝胆病杂志》;第38卷(第3期);第515-520页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115161283A (en) | 2022-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115161283B (en) | Composition for directional differentiation and culture of liver portal bile duct cancer-derived organoids and application thereof | |
| CN110592022B (en) | Special culture medium for lung tumor organoid and 3D culture method without stent | |
| CN112210537B (en) | Liver cancer organoid and culture method, culture medium for culture and application thereof | |
| CN112522201A (en) | Culture medium and culture method for bladder cancer organoid | |
| CN112592896B (en) | Culture solution for lung adenocarcinoma organoid and culture method thereof | |
| CN108504625B (en) | Mouse fibroblast and application thereof | |
| CN114736870B (en) | Salivary gland-like cystic carcinoma organoid and culture method, culture medium and application thereof | |
| CN111534477B (en) | Method for culturing primary epithelial stem cell balls of lung tissue of mouse | |
| CN113308437A (en) | Culture medium, method and kit for rapidly culturing bone metastasis cancer organoids | |
| CN112760289B (en) | Special culture medium for breast cancer organoid and 3D culture method | |
| CN113278586A (en) | Culture medium and culture method for culturing thyroid cancer organoid | |
| WO2023217128A1 (en) | Gastric mucosal epithelial precursor-like cell, and preparation method therefor and use thereof | |
| Hong | Fat grafts enriched with adipose-derived stem cells | |
| CN116590232A (en) | Thyroid cancer organoid, culture medium and culture method | |
| CN116875553A (en) | Mouse colorectal cancer organoid and preparation method and application thereof | |
| CN116536265A (en) | Special organoid culture medium for liver cancer, culture method and passage method | |
| WO2022213704A1 (en) | High-migration mesenchymal stem cell, and preparation method therefor and application thereof | |
| CN114736865B (en) | Salivary gland malignant polymorphic adenoma 3D organoid and culture method and application thereof | |
| CN113444679B (en) | Human lacrimal gland stem cells and differentiation culture method and application thereof | |
| CN116536264A (en) | Special serum-free culture medium for colon cancer organoids | |
| CN116024159A (en) | Method for constructing murine skin organoids | |
| CN111979177B (en) | Preparation method of human bile duct epithelial cells and culture medium thereof | |
| CN110396501B (en) | Three-dimensional spheroid culture method for maintaining dryness of breast cancer stem cells in vitro | |
| CN117106724A (en) | H3K27M mutant spinal glioma cell and culture method thereof | |
| CN118345040A (en) | Novel culture medium for culturing colorectal cancer organoids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |